Login / Signup

Non-Targeted Metabolomic Analysis Reveals Serum Phospholipid Alterations in Patients with Early Stages of Diabetic Foot Ulcer.

Ignacio I Álvarez-RodríguezEduardo Castaño-TostadoDavid G García-GutiérrezRosalía Reynoso-CamachoJuana Elizabeth Elton-PuenteAlicia Barajas-PozosIza Fernanda Pérez-Ramírez
Published in: Biomarker insights (2020)
Diabetic foot ulcer (DFU) is a common complication of type 2 diabetes mellitus (T2DM) characterized by ulcer formation, which can lead to the amputation of lower extremities. However, the metabolic alterations related to this complication are not completely elucidated. Therefore, we carried out a metabolomic analysis of serum samples obtained from T2DM adult patients diagnosed with diabetic foot ulcer in a cross-sectional, observational, and comparative study. Eighty-four volunteers were classified into the following groups: without T2DM (control group, n = 30) and with T2DM and different stages of diabetic foot ulcer according to Wagner-Meggitt classification system: DFU G0 (n = 11), DFU G1 (n = 14), DFU G2 (n = 16), and DFU G3 (n = 13). The non-target metabolomic profile followed by chemometric analysis revealed that lysophosphatidylethanolamine (16:1) could be proposed as key metabolite related to the onset of diabetic foot ulcer; however, this phospholipid was not affected by diabetic foot ulcer progression. Therefore, further studies are necessary to validate these phospholipids as biomarker candidates for the early diagnosis of diabetic foot ulcer in T2DM patients.
Keyphrases
  • end stage renal disease
  • fatty acid
  • chronic kidney disease
  • type diabetes
  • peritoneal dialysis
  • drug delivery
  • weight loss
  • cancer therapy
  • cross sectional
  • patient reported